---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-001523"
form_type: "8-K"
ticker: "PDEX"
cik: "0000788920"
company_name: "PRO DEX INC"
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:21:32.446362+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pro-Dex Q1 FY2024 net loss $615k; sales up 8% to $11.9M; includes $2.6M unrealized loss on investment

## Summary
- Net loss of $615k ($0.17 diluted) vs net income of $1.2M ($0.33) in prior-year quarter.
- Net sales rose 8% to $11.9M; driven by $1.8M increase in handpiece repairs, offset by $0.7M drop in NRE.
- Gross margin improved 4 ppts to 31% due to absence of $450k repair costs from prior year.
- Unrealized loss on investments of $2.6M (mainly Monogram Orthopaedics warrant) caused the net loss.
- CEO cited $1.1M in new Thoracic driver product sales and completion of Franklin facility transition.

## SEC filing metadata
- accession: 0001079973-23-001523
- form_type: 8-K
- ticker: PDEX
- cik: 0000788920
- company_name: PRO DEX INC
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/788920/000107997323001523/0001079973-23-001523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/788920/000107997323001523/pdex_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-001523
- JSON: https://secwatch.observer/filing/0001079973-23-001523.json
- Plain text: https://secwatch.observer/filing/0001079973-23-001523.txt

## Key facts
- Earnings Releases
  PRO DEX INC reported fiscal 2024 first quarter ended September 30, 2023 results: revenue $11.9 million, net income net loss of $615,000, or $0.17 per diluted share.
  - Period: fiscal 2024 first quarter ended September 30, 2023
  - Revenue: $11.9 million
  - Net income: net loss of $615,000, or $0.17 per diluted share
  - Result: reported results
  source text: the first quarter of fiscal year 2024 with the Securities and Exchange Commission today. Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our
  evidence_url: https://www.sec.gov/Archives/edgar/data/788920/000107997323001523/0001079973-23-001523-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.